Delivery Order SPE2DB20D1004-SPE2DB25F1678
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $43,275.69. This firm fixed-price, non-set-aside contract is scheduled for completion by August 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, eczema, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- On August 15, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $97,415.40 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $7,827.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $3,418.92. This non-competitive, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $42,441.91. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $37,021.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a delivery order valued at $22,237.80 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 21, 2025. This firm fixed-price, non-competitive set-aside contract is scheduled for completion by August 22, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for moderate-to-severe atopic dermatitis,...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25F1678Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens valued at $15,457.90. This is a firm fixed-price, non-set-aside contract with a completion date of September 4, 2025, and performance location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis, representing a specialty pharmaceutical product critical to military and federal healthcare operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. As the prime contractor under this comprehensive pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of brand-name and generic medications, vaccines, and medical devices to support military healthcare programs globally. The company's selection through competitive procedures and its role as a primary pharmaceutical vendor underscore its significance in the federal medical supply chain serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.5k | 9/3/25 |